South Rampart Pharma, Inc.

In this follow-up article with Pharmaceutical Executive, South Rampart Pharma, Inc. CEO Hernan Bazan, MD, DFSVS, FACS discusses: ✅ Progress in clinical development, including Phase 2 trials ✅ The NIH’s critical role in funding non-addictive pain therapies ✅ The importance of designing rigorous, objective pain endpoints in trials  With the NIH HEAL Initiative and a strategic mix of non-dilutive and private funding, companies like South Rampart Pharma, Inc. are working to bring safer pain relief options to patients.     🔗 Read the full article: https://lnkd.in/g2-6aqkz #PainManagement #NonAddictiveMedication #PharmaInnovation #OpioidCrisis #Healthcare #ClinicalTrials

📹 Hernan Bazan, MD, DFSVS, FACS, CEO of South Rampart Pharma, Inc., discusses his company’s current pipeline.

The opioid and fentanyl crisis underscores an urgent need for safer, non-addictive pain treatments.     South Rampart Pharma, Inc. CEO Hernan Bazan, MD, DFSVS, FACS recently spoke with Pharmaceutical Executive about our innovative approach to developing novel non-opioid analgesics.    Highlights include: ✅ Progress advancing our lead candidate, SRP-001, into Phase 2 clinical trials ✅ Leveraging support from NIH’s HEAL Initiative ✅ Designing scientifically rigorous and clinically meaningful pain trial endpoints     Read the full interview: https://lnkd.in/gh7SvZRt     #PainManagement #PharmaInnovation #OpioidCrisis #Healthcare 

🚀 Exciting news! South Rampart Pharma, Inc. CEO Hernan Bazan, MD, DFSVS, FACS Bazan recently joined Jeff Harmon on "Conversations Life Science Leaders Aren’t Having" to share his journey between the operating room and the C-suite—and South Rampart Pharma, Inc.’s work against the #opioidcrisis.       💡 With growing investor and regulatory interest in opioid alternatives, many solutions—like NaV1.8 and NaV1.7 inhibitors—are emerging. But unlike these peripherally targeted approaches, South Rampart’s SRP-001 is a next-generation, centrally acting novel non-opioid pain candidate that avoids liver and kidney toxicity and addictive risks of current options. Now FDA fast-tracked, SRP-001 has the potential to transform pain care and narrow the opioid gap.      🎧 Don’t miss this insightful conversation on innovation, execution, and the capital-efficient model driving South Rampart’s success. Listen here: https://lnkd.in/gnw_dfGs 

Non-opioid #pain therapies are gaining momentum with Vertex’s newly approved Journavx targeting Nav 1.8 inhibitors at the forefront—yet real-world uptake remains uncertain. This BioSpace article by Tristan Cesar Mañalac highlights both the promise of next-generation pain relievers like South Rampart Pharma, Inc.'s SRP-001—which dodges the toxicity and addictive pitfalls of current options—and the enduring role of cheaper #opioids. Our CEO Hernan Bazan, MD, DFSVS, FACS discusses how, unlike peripherally targeted approaches such as NaV inhibitors, SRP-001 works centrally, potentially tackling complex and refractory pain states. While insurers weigh cost and efficacy, these novel therapies will reshape the pain space and narrow the opioid gap, but don’t expect opioids to disappear overnight.   South Rampart Pharma, Inc. continues to be recognized for the massive potential of SRP-001 as a non-addictive, non-toxic, non-opioid treatment for pain.   Read the full article here:  https://lnkd.in/g89-8rW6

𝐁𝐢𝐠 𝐧𝐞𝐰𝐬 𝐢𝐧 𝐩𝐚𝐢𝐧 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 – 𝐭𝐡𝐞 𝐅𝐃𝐀 𝐣𝐮𝐬𝐭 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐚 𝐟𝐢𝐫𝐬𝐭-𝐢𝐧-𝐜𝐥𝐚𝐬𝐬 𝐧𝐨𝐧-𝐨𝐩𝐢𝐨𝐢𝐝 𝐩𝐚𝐢𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜. Vertex Pharmaceuticals #Journavx has officially entered the market as a new alternative to opioids for acute pain, generating significant attention across the industry. This comes at a critical time, as the opioid epidemic continues to devastate communities with nearly 84,000 opioid-related deaths in 2024. While analysts see blockbuster potential (projecting $1B in sales by 2028), questions remain. Pricing, clinician adoption, and insurance coverage will play major roles in determining how widely Journavx is used. At $15.50 per pill, it’s significantly more expensive than generic opioids ($0.50 per pill), though Vertex has set up a patient savings program to improve access. Beyond Vertex, other biotechs including Algiax Pharmaceuticals, Tris Pharma, South Rampart Pharma, Inc., Latigo Biotherapeutics, Inc., and Cara Therapeutics - are racing to develop their own non-opioid pain treatments. The pain therapeutics market is expected to surpass $106.7B by 2032, and it's clear there is huge demand for safer, effective alternatives. Could this be the turning point in the fight against opioid dependency? And what will it take for non-opioid treatments to gain widespread adoption? #biotech #pharma #painmanagement #drugdevelopment #opioidcrisis

I was honored to have the opportunity to speak with Brian Gormley and contribute to his report this morning in The Wall Street Journal which discussed Robert F. Kennedy Jr.’s HHS confirmation and its impact on #biotech and #lifesciences. His leadership signals the potential for faster FDA approvals, streamlined NIH funding, and expanded preventive health initiatives—key drivers for #innovation and #investment. However, concerns around stricter vaccine regulations highlight the need for a balanced approach that fosters growth while ensuring rigorous oversight. The future of biotech hinges on policies that accelerate breakthrough therapies without stifling the pipeline of new treatments. Read the full article here: https://lnkd.in/gM77u-4T

Insights from a Global Health Leader: Breakfast with John ‘Jack’ Rockefeller    It was a privilege to meet with JD Rockefeller JD MPH DrPH — former Associate Dean at Dartmouth’s Geisel School of Medicine and a visionary in global health. These follow-up discussions centered on South Rampart Pharma, Inc. roadmap for SRP-001, our non-opioid solution designed to meet the demand for safer, more effective pain therapeutics.    Although the opioid crisis is most severe in the U.S., global health experts increasingly recognize it as a worldwide challenge. Countries like Canada, Australia, and parts of Europe also report rising misuse and overdose rates, driven by evolving prescription practices, illicit fentanyl, and limitations of current pain medicines.    Jack’s expertise in health leadership and academic innovation provides us with invaluable strategies for accelerating our clinical trials and forging partnerships. We look forward to leveraging his insights as we advance SRP-001 for patients worldwide.    #NonOpioid #Innovation #Healthcare #GlobalHealth #Pain

Check out this engaging conversation with our CEO, Dr. Hernan Bazan, MD, DFSVS, FACS, and host Ira S. Pastor on the "Progress, Potential, And Possibilities" podcast—already surpassing 2.5k views. Dr. Bazan joins an accomplished roster of guests, including Dr. Anthony Fauci (Georgetown, former NIAID/NIH Director), Dr. Craig Venter (genomics pioneer), and 2023 Nobel Laureate Dr. Drew Weissman (mRNA vaccines). In this discussion, Dr. Bazan examines the evolving pain landscape and introduces SRP-001, our CNS-targeted, non-opioid candidate that complements peripheral NaV1.8 approaches, such as Vertex’s recent success.    Learn more about our approach here: https://lnkd.in/gY4vwPvg #PainRelief #Pharmaceuticals #Innovation #Healthcare #LifeSciences

Heather McKenzie’s BioSpace’s latest coverage of Vertex Pharmaceuticals’s FDA approval for suzetrigine (Journavx) spotlights a new era in non-addictive pain management and the rising demand for safer, non-opioid therapies. On the heels of this milestone, South Rampart Pharma, Inc.’s lead asset, SRP-001, continues to gather attention for its potential in this massive growth space and is well-positioned with its central-acting mechanism and lack of hepatotoxicity—an approach that could complement peripheral agents and support effective, multi-modality analgesia.  Read the full article here: https://lnkd.in/g_rwyQ4V #NonOpioidTherapies #HealthcareInnovation #SouthRampartPharma #Pharma